ProFem is a Vienna based pharmaceutical company founded in 2012 with the focus on the clinical development of innovative drugs for the treatment of gynecological diseases.
Our main focus, especially with the lead candidate “Candiplus®”, lies on infections of the lower urogenital tract, diseases which are frequently associated with the growth of so-called biofilms. This group of infections represents a huge and so far unsolved medical problem in gynecology.
Founder and CEO of ProFem GmbH, biochemist and medical doctor, specialized in gynecology and obstetrics, focus of research on uterine physiology and pathophysiology. Additionally more than 10 years of professional experience in start-up companies: project management of chemical development projects (API production, GMP documentation), CEO of start-up companies (pharmaceutical R&D) since 2004.
In her position as Chief Financial Officer (CFO), she is responsible for the financial administration and controlling at ProFem. The Master of Arts of the University of St. Gallen (HSG) has many years of professional expertise in the field of finance. She co-founded VMP St. Gallen Investment Management GmbH in 1990 and, as partner of WKV Investment Holding GmbH, she is responsible for the controlling of the investment portfolio since 2012.
Chief Medical Officer of ProFem, setting up and managing the clinical development program, including relations to competent authorities, clinical operations team and study centres. Board certified in Internal Medicine, Cardiology and Clinical Pharmacology MD, more than 20 years of clinical research experience, as investigator and medical director.
Montavit has been producing medicines as a family business in Absam, Tyrol, for over 70 years and exports to more than 70 countries worldwide. The strategic alliance with ProFem is seen as a key collaboration in a gynecological research project. As part of this cooperation with ProFem, Montavit is responsible for providing support in the clinical development of the product and for the Austrian and German study centers, in which the new medication will be tested. www.montavit.com
Former director of Research and Development of Boehringer Ingelheim Austria, in this function one of the main initiators of the foundation of the Institute of Molecular Pathology (IMP) and the Biocenter of the University of Vienna, former vice-rector for research at the Veterinary University of Vienna. Broad international experience in the development of innovative medicines from discovery to registration.
Former Head of the Departments of Medicinal Chemistry, Universities of Frankfurt and Vienna. Broad experience in organic and medicinal chemistry, drug discovery and development and translational sciences related to this field. Former advisor to UNIDO and IAEA, former president of EUFEPS, first chairman of the scientific committee of IMI (Innovative Medicines Initiative) of the European Commission.
Wolfgang Vilsmeier is a well-known and recognized german brazilian entrepreneur based in St. Gallen, Switzerland. He holds a Master degree in economics, social sciences and law from the University of St. Gallen, HSG. He is founding partner and Chairman of VMP St. Gallen Investment Management GmbH and WKV Investment Holding GmbH and is a highly reputed expert in effective strategic management.
Andreas Jank is attorney at law with a focus on pharmaceutical law, corporate finance and M&A. He holds a PhD in Law and is founding partner of Jank Weiler Operenyi attorneys at law, a Viennese law firm which is partner of Deloitte Legal since 2018.